Ira Pastan
Affiliations: | National Institutes of Health, Bethesda, MD |
Area:
Molecular BiologyWebsite:
http://ccr.nci.nih.gov/staff/staff.asp?profileid=5782Google:
"Ira Pastan"Mean distance: 14.27 (cluster 32) | S | N | B | C | P |
Cross-listing: Neurotree
Children
Sign in to add trainee| Itai Benhar | grad student | ||
| Shigetada Nakanishi | grad student | NIH (Neurotree) | |
| Benoit de Crombrugghe | post-doc | ||
| John A. Hanover | post-doc | NIH (NCI) | |
| Frederick R. Maxfield | post-doc | NIH | |
| Kenneth Yamada | post-doc | NIH | |
| Robert J. Lefkowitz | post-doc | 1968-1970 | NIH |
| Harold Elliot Varmus | research scientist | 1968-1970 | NIH (DevTree) |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Mazor R, Pastan I. (2020) Immunogenicity of Immunotoxins Containing Exotoxin A: Causes, Consequences, and Mitigation. Frontiers in Immunology. 11: 1261 |
| Inoue S, Tsunoda T, Riku M, et al. (2020) Diffuse mesothelin expression leads to worse prognosis through enhanced cellular proliferation in colorectal cancer. Oncology Letters. 19: 1741-1750 |
| Liu XF, Wei J, Zhou Q, et al. (2020) Immunotoxin SS1P is rapidly removed by proximal tubule cells of kidney, whose damage contributes to albumin loss in urine. Proceedings of the National Academy of Sciences of the United States of America |
| Zheng Z, Okada R, Kobayashi H, et al. (2019) Site-specific PEGylation of anti-mesothelin recombinant immunotoxins increases half-life and anti-tumor activity. Molecular Cancer Therapeutics |
| Fleming BD, Urban DJ, Hall M, et al. (2019) The engineered anti-GPC3 immunotoxin, HN3-ABD-T20, produces regression in mouse liver cancer xenografts via prolonged serum retention. Hepatology (Baltimore, Md.) |
| Cerise A, Bera TK, Liu X, et al. (2019) Anti-Mesothelin Recombinant Immunotoxin Therapy for Colorectal Cancer. Clinical Colorectal Cancer |
| Bera TK, Liu W, Leshem J, et al. (2019) Generation of a Transgenic BALB/c Mouse Line With Selective Expression of Human Mesothelin in Thyroid Gland: Application in Mesothelin-targeted Immunotherapy. Journal of Immunotherapy (Hagerstown, Md. : 1997) |
| Leshem Y, Pastan I. (2019) Exotoxin Immunotoxins and Anti-Tumor Immunity: From Observations at the Patient's Bedside to Evaluation in Preclinical Models. Toxins. 11 |
| Leshem Y, King E, Reiter Y, et al. (2019) Abstract A142: Anti-mesothelin immunotoxins induce markers of immunogenic cell death and when injected locally into AE17M mesothelioma tumors enhance the effect of CTLA-4 blockade Cancer Immunology Research. 7 |
| Kreitman R, Gorelik D, Stetler-Stevenson M, et al. (2019) Abstract CN07-03: Recombinant immunotoxins for hematologic malignancies Molecular Cancer Therapeutics. 18 |